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Antibodies are required to control blood-stage forms of African trypanosomes in humans and animals. Here,
we report that intradermal infections by low numbers of African trypanosomes are controlled by innate
resistance but prime the adaptive immune response to increase susceptibility to a subsequent challenge. Mice
were found 100 times more resistant to intradermal infections by Trypanosoma congolense or Trypanosoma
brucei than to intraperitoneal infections. B cell–deﬁcient and RAG2
2/2 mice are as resistant as wild-type mice
to intradermal infections, whereas inducible nitric oxide synthase (iNOS)
2/2 mice and wild-type mice treated
with antibody to tumor necrosis factor (TNF) a are more susceptible. We conclude that primary intradermal
infections with low numbers of parasites are controlled by innate defense mediated by induced nitric oxide
(NO). CD1d
2/2 and major histocompatibility complex (MHC) class II
2/2 mice are more resistant than wild-
type mice to primary intradermal infections. Trypanosome-speciﬁc spleen cells, as shown by cytokine
production, are primed as early as 24 h after intradermal infection. Infecting mice intradermally with low
numbers of parasites, or injecting them intradermally with a trypanosomal lysate, makes mice more susceptible
to an intradermal challenge. We suggest that intradermal infections with low numbers of trypanosomes or
injections with trypanosomal lysates prime the adaptive immune system to suppress protective immunity to an
intradermal challenge.
African trypanosomes are extracellular hemoprotozoa.
T. brucei gambiense and T. brucei rhodesiense cause
sleeping sickness in humans. Sleeping sickness is an
emerging disease in Africa [1]. There is no vaccine
available against human African trypanosomiasis, and
chemotherapy is less than satisfactory [2]. Trypanosoma
congolense, T. brucei brucei,a n dTrypanosoma vivax are
pathogens for livestock [3]. Although there are differ-
ences between the different species of African trypano-
somes, they all share major features. African
trypanosomes cause persistent infections of the blood.
They survive in humans and animals by complex eva-
sion mechanisms [4], including antigenic variation [5–
7] and immunosuppression [8–12]. They are covered
with a glycoprotein coat of a single molecular species,
the variant surface glycoprotein (VSG) [5, 7]. The VSG
is anchored into the membrane via a glycolipid, a gly-
cosylphosphatidylinositol [13, 14]. Infections of mam-
malian hosts are associated with cycles of parasitemia
and expression of new VSGs [5, 7, 15]. Each new VSG
elicits a strong immunoglobulin (Ig) M anti-VSG re-
sponse [5], which leads to phagocytosis of the trypa-
nosomes by macrophages of the liver via complement
receptor CR3 [16–18].
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trypanosome-infected tsetse ﬂies [3]. The labellar teeth of the
proboscis of the tsetse ﬂy cut small capillaries. Blood leaking
from these capillaries forms a small pool under the skin and is
sucked up through the proboscis into the pharynx [19]. The
bite by the infected tsetse ﬂy results in an infection in the skin
of the bitten human or animal. It was found that the
salivary gland of the tsetse ﬂy had to contain at least 300–450
trypanosomes to establish infections in humans [20]. The
trypanosomes migrate from the skin into the blood via the
lymph system [15, 21].
Past research into the immunobiology of mice experimentally
infected with African trypanosomes has mostly been based on
the immune responses of mice infected via the intraperitoneal
route [4, 8, 10, 22–25]. Although these studies have provided
great insight into the host-parasite relationship, they have ig-
nored the very early immunological events triggered by the in-
fecting parasites. This situation prompted us to develop an
animal model based on intradermal infections.
We have, for the ﬁrst time, provided evidence that in-
tradermal infections by low numbers of trypansomes are con-
trolled by innate resistance and that the process of innate
resistance is accompanied by the priming of the adaptive im-
mune system resulting in increased susceptibility to a sub-
sequent intradermal challenge. We propose that these ﬁndings
have important bearings on the development of vaccines against
African trypanosomiases.
MATERIALS AND METHODS
Mice
The studyincluded8–10-week-oldfemaleBALB/c,C57BL/6and
outbred Swiss mice (CD1), purchased from the Animal Re-
sourceCenter,UniversityofSaskatchewan;6–8-week-oldfemale
CD1d
2/2, MHC class II
2/2, B cell–deﬁcient (lMT), and iN-
OS
2/2 mice, with either BALB/c or B6 background, purchased
from the Jackson Laboratory; and RAG2
2/2 B6 mice, purchased
from Taconic. The mice were housed in polycarbonate cages on
sawdust and allowed free access to food and water throughout
the experiments, according to recommendations of the
Canadian Council of Animal Care.
Parasites and Parasite Lysates
The origin of T. congolense, strain Trans Mara, clone
TC13 used in this study has been described elsewhere [26].
T. congolense,c l o n eT C 1 4 ,ac l o n ed i f f e r e n tf r o mT C 1 3 ,w a s
obtained as described elsewhere [27]. T. brucei brucei, strain
10–26 and strain Whatat 1.1, were obtained from Dr Terry
Pearson, University of Victoria, Victoria, British Columbia.
Frozen parasite stabilates from liquid nitrogen were thawed
and used to intraperitoneally infect outbred CD1 mice that
had been immunosuppressed with cyclophosphamide
(Cytoxan; 200 mg/body weight) 48 h earlier [26]. The para-
sites used for experimental infections were puriﬁed by di-
ethylaminoethyl cellulose anion exchange columns [28] from
the blood of infected CD1 mice. A known number of isolated
parasites which had been frozen, thawed, and then sonicated,
were used as lysate antigen.
Infection, Immunization, and Determination of Parasitemia and
Survival Time
The parasites, enumerated with use of a hemocytometer, were
injected in a volume of 20 lL intradermally into a hind footpad
of mice. To make sure that low doses of parasites used for in-
tradermal infections were potentially infectious, groups of
control mice were infected intraperitoneally with these low
doses. Parasitemia and survival time were determined as de-
scribed elsewhere [29].
Antibodies and Enzyme-Linked Immunosorbent Assay
Puriﬁed monoclonal antibody (mAb) rat anti-mouse TNF-a,
clone MP6-XT22 (IgG1, j), was purchased from eBiosciense.
OptEIA cytokine detection sets were obtained from BD Bio-
sciences.
Ex Vivo Cytokine Production
Single cell suspensions of spleens and popliteal lymph nodes of
mice were cultured at an optimal cell density (5 3 10
6 cells/mL/
well for spleen cells and 2 3 10
6 cells/mL/well for lymph node
cells) in 24-well plates (Becton Dickinson) for 48 h at 37C.
Culture supernatants were harvested and stored at 280Cu n t i l
use. Cytokines in the culture supernatants were determined by
enzyme-linked immunosorbent assay, as described elsewhere
[30].
Statistical Analysis
Data are presented as means 6 standard errors (SEs). Two-
samplet tests comparingpercentageswereusedtodetermine the
signiﬁcance of differences in infectivity data. Log-rank tests were
used to determine the signiﬁcance of differences in survival
curves. Differences were considered statistically signiﬁcant at
P , .05.
RESULTS
Resistance to Parasite Challenge in Mice Infected Intradermally
or Intraperitoneally with T. congolense or T. brucei
BALB/c mice are highly susceptible to T. congolense infections
and die within 8–10 days after intraperitoneal infection with
10
3 T. congolense TC13, whereas relatively resistant C57BL/6
mice survive for .100 days [4]. BALB/c and C57BL/6 mice
were infected either intraperitoneally or intradermally in
ah i n df o o t p a dw i t hv a r y i n gd o s e so fT. congolense TC13. All
mice infected intraperitoneally with 10
1–10
4 T. congolense
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(Figure 1. A, C), and all BALB/c mice died by day 8 after
infection (Figure 1A). Neither BALB/c nor C57BL/6 mice
infected intradermally with 10
1 or 10
2 T. congolense TC13
showed parasitemia (Figure 1 B, D). They survived with no
signs of disease until day 30 when the experiment was
terminated. All mice infected intradermally with 10
3 or 10
4
parasites developed parasitemia (Figure 1 B, D), but the
prepatent periods of intradermal infections were, prolonged
by >2 days, compared with intraperitoneal infectious
(P , .05). All BALB/c mice infected with these higher
numbers of parasites died by day 12 after infection (Figure 1B).
Figure 1. The intradermal route of infection of mice by Trypanosoma congolense or Trypanosoma brucei requires a dose up to100-fold higher than does
the intraperitoneal route to cause parasitemia and death. A–D, Groups of 4 mice were infected with varying doses of T. congolense, clone TC13. A, BALB/
c mice were infected intraperitoneally, B, BALB/c mice were infected intradermally in a hind footpad, C, D, C57BL/6 mice were infected intraperitoneally
(C) and C57BL/6 mice were infected intradermally in a hind footpad (D). E, Groups of 5–6 BALB/c mice were infected intradermally into a hind footpad
with varying doses (10
2–10
5) of moderately virulent T. brucei brucei, strain 10–26, or intraperitoneally with 10
2 T. brucei brucei, strain 10–26. Parasitemia
was monitored after the infection.
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2 T. brucei
brucei, strain 10–26, led to parasitemia in all mice (Figure 1E). In
contrast, intradermal infections of BALB/c mice with 10
2
T. brucei brucei, 10–26, caused neither parasitemia nor disease.
Ad o s eo f1 0
3 T. brucei brucei, strain 10–26, led to parasitemia in
50% of the infected mice (Figure 1E). Intraperitoneal in-
fections with 5 parasites of highly virulent T. brucei brucei,s t r a i n
Whatat 1.1, caused parasitemia and disease in both BALB/c and
C57BL/6 mice (not shown). BALB/c mice infected intradermally
with highly virulent T. brucei brucei, strain Whatat 1.1, also
showedlowersusceptibilitythanwheninfectedintraperitoneally.
Intradermal infections with 5 or 10 parasites led to parasitemia
in only 10% of the infected mice (not shown). C57BL/6 mice
infected intradermally with 5 or 10 T. brucei, strain Whatat 1.1,
did not develop parasitemia and only 80% of C57BL/6 mice
infected intradermally with 10
2 T. brucei, strain Whatat 1.1 de-
veloped parasitemia (not shown). Although there are differences
in the outcomes of infections, depending on the strain of mouse
and the virulence of the trypanosomes, the results clearly show
that responses to intradermal infections have an up to 100-fold
higher probability of preventing parasitemia and disease com-
pared with intraperitoneal infections.
Resistance to Intradermal Infections by Low Numbers of
T. brucei or T. congolense without Antibodies or T Cells
It is well established that in intraperitoneal infections by
T. brucei [10, 31] or T. congolense [18, 23], there is an absolute
requirement for antibodies to VSG for the control of
parasitemia. To determine whether anti-VSG antibodies might
be required for the resistance against intradermal infection
with few parasites, wild-type C57BL/6 mice, B cell–deﬁcient
mice (lMT) and RAG2
2/2 C57BL/6 mice were used. All wild-
type mice infected intraperitoneally with either 10
2 T. brucei
brucei, strain 10–26, or 10
2 T. congolense TC13, develop
parasitemia (Figure 2A). None of the wild-type mice develop
parasitemia after intradermal infection with either 10
2
T. brucei brucei, strain 10–26, or 10
2 T. congolense TC13
(Figure 2B). Surprisingly, none of the B cell–deﬁcient mice
(Figure 2C) or the RAG2
2/2 mice (Figure 2D) develop
parasitemia or become sick with this low-dose intradermal
infection. We conclude that B cells, anti-VSG antibodies, and
T cells are not required for the resistance to intradermal
infection with low numbers of trypanosomes. These results
indicate that the resistance to intradermal infections is due to
innate defense mechanisms.
Figure 2. B cell–deficient (lMT) and RAG2
2/2 mice are as resistant as wild-type mice when infected intradermally with low doses (10
2)o f
Trypanosoma brucei or Trypanosoma congolense. A, Wild-type C57BL/6 mice were infected intraperitoneally with 10
2 T. congolense, clone TC13 or 10
2
T. brucei brucei, strain 10–26. B–D, Groups of 5–6 wild-type C57BL/6 mice (B), B cell–deficient (lMT) (B
2/2) mice (C), or RAG2
2/2 mice (D) were infected
intradermally in a hind footpad with either 10
2 T. congolense, clone TC13 or 10
2 T. brucei brucei, strain 10–26. Parasitemia was monitored after the
infection.
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Infections by Low Numbers of T. congolense
There is ample evidence that macrophage-derived NO has
a detrimental effect on African trypanosomes [32, 33]. We ex-
amined whether induced NO might be a major mediator of the
observed innate resistance to intradermal infections. Wild-type
and iNOS
2/2 C57BL/6 mice were infected intradermally with 5
3 10
2 T. congolense TC13. None of the infected wild-type mice
developed parasitemia (Figure 3A), but all infected iNOS
2/2
mice did (P , .001) (Figure 3B). The results indicate that iN-
OS
2/2 mice are more susceptible to T. congolense infection than
wild-type mice. Thus, we conclude that induced NO is a major
mediator controlling primary intradermal infections by T. con-
golense.
TNF-a Mediation of Resistance to Intradermal Infections by Low
Numbers of T. congolense
TNF-a enhances the induction of NO synthase [34] and has
been shown, under certain conditions, to mediate control of
intradermal infections by T. congolense [30]. C57BL/6 mice were
injected intradermally with 25 lg/mouse of anti–TNF-a mAb or
isotype control rat IgGs on the day before infection and day 3
after infection. Mice were infected in the same footpad on day
0w i t h53 10
2 T. congolense TC13. None of the 5 control mice
had detectable parasitemia (Figure 3C), but 4 of the 6 mice
(67%) given anti–TNF-a mAb did develop parasitemia
(P , .025) (Figure 3D). The results indicate that TNF-a is
a mediator of protection against primary intradermal infections
by T. congolense.
Effect of Adaptive Immune Responses on Resistance to Primary
Intradermal Infections by T. congolense
We further considered whether T cells might have an inﬂuence
on the outcome of intradermal infections by trypanosomes. We
infected groups of 10wild-type, CD1d
2/2, and MHC class II
2/2
C57BL/6 mice intradermally into a hind footpad with 10
4
T. congolense TC13. All of the infected wild-type C57BL/6 mice
developed parasitemia (Figure 4A). None of the infected
Figure 3. Inducible nitric oxide synthase (iNOS)
2/2 mice and wild-type mice treated with monoclonal antibody to tumor necrosis factor (TNF) a are
more susceptible than wild-type mice to intradermal infection with Trypanosoma congolense. A, B, Groups of 5 wild-type C57BL/6 (A) and B, iNOS
2/2
C57BL/6 (B) mice were infected intradermally into a hind footpad with 5 3 10
2 T. congolense, clone TC13. C, C57BL/6 mice were injected intradermally
into a hind footpad with isotype control rat immunoglobulin G (25 lg/mouse) on day 21 and day 3 after infection. D, C57BL/6 mice were injected
intradermally into a hind footpad with anti–TNF-a monoclonal antibodies (25 lg/mouse) on day 21 and day 3 after infection. On day 0, mice were
infected intradermally into the same footpad with 5 3 10
2 T. congolense, clone TC13. Parasitemia was monitored after the infection. Parasitemia was
significantly enhanced in the iNOS
2/2 mice (P , .001) and in anti–TNF-a–treated mice (P , .025).
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2/2 mice (P , .00001) (Figure 4B) and only 2 (22%) of
the 9 MHC class II
2/2 mice (P , .001) (Figure 4C) developed
parasitemia. CD1d
2/2 BALB/c mice infected intradermally with
5 3 10
2 T. congolense TC13 were also more resistant than wild-
typeBALB/cmice(notshown).Thus,bothCD1d
2/2 andMHC
class II
2/2 mice were more resistant than wild-type mice. The
results indicate that CD1d-restricted natural killer T cells and
MHC class II–restricted CD4
1 T cells are induced by in-
tradermal infections with T. congolense and exert a suppressive
effect on the protective mechanism(s).
Systemic Adaptive Immune Response Within 24 h After
Intradermal Infection
BALB/c mice were infected intradermally in a hind footpad with
10
2 T. congolense TC13. On days 1, 2, 3, 5, and 8 after infection,
spleen cells and popliteal lymph node cells were cultured with or
without lysates of T. congolense TC13 (equivalent to10
5 para-
sites/well) for 48 h. Cytokines (TNF-a, interleukin (IL) 6, IL-10,
and interferon (IFN) c) in the supernatants were determined by
enzyme-linked immunosorbent assay (Figure 5). Signiﬁcant
trypanosome-speciﬁc production of IL-10 and IFN-c were
obtained with spleen cells collected at 24 h after intradermal
infections. Thus, these observations show that priming of try-
panosome-speciﬁc T cells in the spleen occurred as early as 24 h
after intradermal infection.
Intradermal Infections With 10
2 T. congolense Render BALB/c
and C57BL/6 Mice More Susceptible to a Subsequent
Intradermal Challenge With a Different Variant of T. congolense
We considered that primary intradermal infections with low
doses of trypanosomes might, after a certain lapse of time,
induce a measure of protection against a subsequent chal-
lenge. Thus, both BALB/c and C57BL/6 mice were infected
intradermally in a hind footpad with 10
2 T. congolense,c l o n e
TC13, 3 times, at weekly intervals. These mice did not develop
any detectable parasitemia during this period of low-dose
exposure. Ten days after the last infection, control (Figure 6A,
D) and preexposed mice (Figure 6B, E) were challenged (10
3
and 10
4 TC14 for BALB/c and C57BL/6, respectively) in-
tradermally in a hind footpad with T. congolense TC14. Par-
asitemia (Figure 6A, B, D, E) and survival time (Figure 6C)
were monitored. To our great surprise, the preexposed mice
Figure 4. CD1d
2/2 mice and major histocompatibility complex (MHC) class II
2/2 mice are more resistant than wild-type mice to intradermal infections
by Trypanosoma congolense. Groups of 10 wild-type C57BL/6 mice (A), CD1d
2/2 C57BL/6 mice (B), or MHC class II
2/2 C57BL/6 mice (C) were infected
intradermally with 10
4 T. congolense, clone TC13. Parasitemia was monitored after infection. Infected CD1d
2/2mice (P , .00001) and MHC class II
2/2
mice (P , .001) showed no or significantly less parasitemia.
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the control mice (P , .05). The preexposed BALB/c mice had
a signiﬁcantly lower survival time (P , .05). All preexposed
BALB/c mice died by day 13, whereas the control mice sur-
vived until day 30, when the experiment was terminated
(Figure 6B). All of the preexposed C57BL/6 mice (Figure 6E)
but none of the control mice (Figure 6D) developed para-
sitemia. Thus, the observations indicate that induction of
a particular immune response on primary intradermal in-
fection leads to enhanced susceptibility to intradermal re-
infection, which is not variant speciﬁc.
Intradermal Injections of Lysates of T. congolense or T. brucei
and Susceptibility to Subsequent Intradermal Challenges by
T. congolense or T. brucei
Because intradermal infections with low numbers of trypano-
somes made the mice more susceptible to intradermal chal-
lenges, we wanted to know whether intradermal injections with
killed trypanosomes might yield similar results. We chose to
inject CD1d
2/2 mice rather than wild-type mice because
CD1d
2/2 mice proved to be more resistant than wild-type mice
to primary infections (Figure 4). CD1d
2/2 B6 mice were
injected intradermally in a hind footpad with lysates of T. con-
golense, clone TC13, equivalent to 10
6 (Figure 7B) or 10
3 para-
sites (Figure 7C). Six weeks later, they were challenged
intradermally in the footpad with 5 3 10
4 T. congolense,c l o n e
TC14. All unprimed control mice developed a moderate level of
parasitemia (Figure 7A) and survived until day 30, when the
experiment was terminated. All mice preexposed to lysate
developed signiﬁcantly higher parasitemia (Figure 7 A, B, C)
(P , .05) and had signiﬁcantly lower survival time than the
control mice (Figure 7D) (P , .01).
BALB/c mice were also intradermally injected with lysate of
highly virulent T. brucei brucei, strain Whatat 1.1, equivalent to
10
2 parasites. Six months later, the preexposed and control mice
were intradermally infected with 10
2 T. brucei, strain 10–26.
Control mice developed neither parasitemia nor disease by day
30, when the experiment was terminated (Figure 7E). All mice
previously injected with the T. brucei lysate, however, developed
parasitemia (Figure 7F) and died by day 30 (not shown). These
results indicate that mice preexposed intradermally to a single
dose of lysate of either T. congolense or T. brucei are rendered
more susceptible to challenge by the respective trypanosomal
species.
Figure 5. Kinetics of (parasite-specific) cytokine production by spleen cells and draining lymph node cells of BALB/c mice infected intradermally with
a low dose of Trypanosoma congolense. Forty BALB/c mice were infected intradermally in a hind footpad with 10
2 T. congolense, clone TC13. At each
time point (days 1, 2, 3, 5, and 8), 8 mice were euthanized. Spleen cells (Spleen) and popliteal lymph node cells (LN) of two mice were pooled. Four sets of
pooled cells were cultured with/without TC13 lysates (equivalent to 10
5 parasites/well) for 48 h. Supernatants were collected and stored at 280C until
use. Concentrations of the cytokines were determined by enzyme-linked immunosorbent assay. Data represent means 6 standard errors of the 4 sets of
pooled cells at each time point. Cytokine values of cultures with antigen are shown. Cytokine values in cultures without antigen were negligible (not
shown). Cytokine values in supernatants of cell cultures of spleens and popliteal lymph nodes of normal mice, cultured with or without antigen, also were
negligible (not shown).
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Experimental infections of mice with African trypanosomes
have provided a wealth of information on the immunobiology
of infections [4, 8–10, 22–25]. For no explicit reason, however,
infections were usually carried out via the intraperitoneal route.
Natural transmissions, by the bites of infected tsetse ﬂies, result
in dermal infections, which subsequently lead, via the lymph
Figure 6. Intradermal infection with 10
2 Trypanosoma congolense, clone TC13, renders mice more susceptible to an intradermal reinfection with
T. congolense, clone TC14. Mice were infected intradermally in a hind footpad with 10
2 T. congolense, clone TC13, 3 times at weekly intervals. These
mice did not develop any detectable parasitemia during this period of low-dose exposure. Ten days after the last infection, the preexposed mice and
unexposed control mice were infected intradermally in a hind footpad with T. congolense, clone TC14. Parasitemia and survival time (in BALB/c mice) was
monitored after infection with T. congolense, clone TC14. A, 6 control BALB/c mice were infected intradermally in a hind footpad with 10
3 T. congolense
TC14. B, 10 BALB/c mice were preexposed to 10
2 T. congolense TC13 and challenged with 10
3 T. congolense TC14. C, Survival times in control and
preexposed mice challenged with 10
3 T. congolense TC14; the survival time in the preexposed mice was significantly (P , .02) shorter than that in the
control mice. D, C57BL/6 control mice were infected with 10
4 T. congolense, TC14. E, Eight C57BL/6 mice preexposed to 10
2 T. congolense TC13 and
challenged with 10
4 T. congolense TC14. *
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intradermal T. congolense or T. brucei challenge. A–E, Groups of 4–6 CD1d
2/2 B6 mice were injected intradermally in a hind footpad with a single
dose of a lysate of T. congolense, clone TC13. Six weeks later, these mice as well as a group of control mice were challenged with 5 3 10
4
T. congolense, clone TC14, intradermally in the footpad. Parasitemia and survival time were monitored. A, Control CD1d
2/2 mice infected with
T. congolense, TC14. B, CD1d
2/2 mice preexposed to lysates of T. congolense, clone TC13 equivalent to 10
6 parasites and infected by T. congolense,
TC14. C, CD1d
2/2 mice preexposed to lysates of T. congolense, clone TC13 equivalent to 10
3 parasites and infected by T. congolense,T C 1 4 .D ,
Survival of control and preexposed mice after challenge with 5 3 10
4 T. congolense, TC14. Survival in the preexposed mice was significantly
(P , .005) shorter than that in the controls. E, Five control BALB/c mice were infected intradermally with 10
2 parasites of moderately virulent
T. brucei, strain 10–26 (control). F, Five BALB/c mice were injected intradermally with parasite lysates (equivalent to 10
2 live parasites/mouse) of
highly virulent T.bruceistrain Whatat 1.1. Six months after this injection, they, together withthecontrol mice(E), wereinfectedintradermallywith10
2
T. brucei, strain 10–26. Parasitemia was monitored after infection.
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only one published report on quantitative experiments of in-
tradermal infections with African trypanosomes [20]. The au-
thors found that low numbers of metacyclic T. brucei
rhodensiense (,3.5–4 3 10
2 parasites) injected intradermally by
tsetse ﬂy bites did not establish an infection of the blood [20].
We have begun to examine how the change in route of in-
fection might affect the conclusions drawn [30, 35, 36]. As re-
ported in this study, we found a much higher susceptibility to
experimentalinfections viatheintraperitonealroutethan via the
intradermal route (Figure 1). The immunological environment
in the peritoneal cavity is obviously profoundly different than in
the dermis. Regarding the intraperitoneal versus intradermal
routes, differences in the outcomes of other infections [37] or
immunizations [38] have been reported.
Intraperitoneal infections of mice with either T. brucei [10,
31] or T. congolense [18, 23] lead to infection of the blood and
absolutely require antibodies to VSG for the control of para-
sitemia. The surprising observation that B cell–deﬁcient (lMT)
as well as RAG2
2/2 mice were as resistant as wild-type mice to
intradermal infection with low numbers of T. brucei or T. con-
golense (Figure 2) demonstrates that this resistance is due to
innate mechanisms. We conclude that B cells, anti-VSG anti-
bodies, and T cells are not required for this resistance. The
enhanced susceptibility of iNOS
2/2 mice (Figure 3) and mice
treated with anti–TNF-a antibody (Figure 3) to intradermal
infections by low numbers of T. congolense indicates that in-
duced NO as well as TNF-a contribute to this resistance. It has
been reported elsewhere that NO produced by macrophages is
detrimental to T. brucei [33] as well as to T. congolense [32].
There is also evidence that induced NO contributes to the
control of the blood-stage forms of T. congolense [23].
What processes might lead to innate resistance to in-
tradermal infections by low numbers of trypanosomes? It has
been shown that T. brucei [39] and T. congolense [40] isolated
from infected blood can have cleavage products of complement
component C3 on their surface. T. brucei [41, 42] as well as
T. congolense [43] have been observed to form ﬁlopodia.
Immune complexes of anti-VSG antibody and complement
have been shown to be shed via ﬁlopodia [43], which, in turn,
can be taken up by macrophages [44]. Thus, it is conceivable
that trypanosomes with iC3b on their surface will temporarily
attach to macrophages via CR3 (CD11b/CD18) [17]. It might
be possible that, even in the absence of anti-VSG antibodies,
a certain threshold number of iC3b-CR3 interactions might
induce formation of ﬁlopodia. We speculate that these
ﬁlopodia might separate from trypanosomes and then are en-
gulfed by macrophages, without harming the trypanosomes
involved. This process might activate these macrophages to
synthesize TNF-a and induce them to synthesize and secrete
NO. Macrophage-derived TNF-a might, in an autocrine
fashion, enhance synthesis of NO by the macrophages [34].
We suggest that all trypanosomes that subsequently attach to
these activated macrophages might be killed by NO secreted by
the activated macrophages.
The fact that CD1d
2/2 as well as MHC class II
2/2 mice are
more resistant to primary intradermal infections (Figure 4) in-
dicates that cells of the adaptive immune system act early to
suppress protective responses. Moreover, local intradermal in-
fection by few trypanosomes results in a very rapid systemic
immune response, as shown by the priming for a trypanosome-
speciﬁc cytokine response in the spleen within 24 h after in-
tradermal infection (Figure 5). These results are in line with our
previous observations [30], which led to a hypothesis of cross-
regulation of natural killer T cells and CD4
1 T cells after in-
tradermal infection by T. congolense [36]. Primary intradermal
infections by few African trypanosomes, associated with innate
resistance, not only failed to generate a long-term protective
immunological state but also resulted in enhanced susceptibility
to intradermal challenges (Figure 6). Even more surprisingly,
intradermal injection with a single dose of killed T. congolense or
T. brucei could induce a suppressive immune response as
demonstrated by enhanced susceptibility to intradermal chal-
lenge by T. congolense or T. brucei (Figure 7). These ﬁndings are
novel.
The mechanisms underlying these observations are presently
unknown. A complete picture of the trypanosome-induced
immunosuppression has not yet emerged [8, 10, 12, 22]. In an
extensive investigation into immunization studies against ma-
laria, covering a period from 1965 to 2010, Guilbride et al [45]
came to the conclusion that Plasmodium sporozoites induce
a skin-stage–initiated immunosuppression inhibiting vaccine
function. We see here a parallel to our results with intradermal
infections by African trypanosomes. Intradermal vaccination
against rabies, however, has been shown to be as safe and im-
munogenic as intramuscular vaccination [46]. Thus, there does
not appear to be an intrinsic property of the skin that necessarily
leads to immunosuppression when a pathogen enters. We
propose that pathogenic Plasmodium and Trypanosoma share
parameters, absent in rabies virus, that induce skin-stage–initi-
ated immunosuppression.
Our observations have changed our perspective on whether
an effective vaccination procedure might be realizable. There is
a widely held concept that antigenic variation of the surface
glycoprotein of African trypanosomes is the major hurdle for
producing a vaccine [47–49]. On the basis of our presentresults,
we do not share this view. We consider immunosuppression,
induced by the trypanosomal infection, the major obstacle for
producing a vaccine. Thus, the major question for the pro-
duction of a potential vaccine is how one can most effectively
prevent the induction of immunosuppression by the trypano-
somes.Toanswerthisquestion,itiscrucialtoclearlyidentifythe
mechanisms of immunosuppression induced by intradermal
injections of trypanosomal lysates. In fact, we consider this line
Innate Resistance to African Trypanosomes d JID 2011:203 (1 February) d 427of investigation a path to developing a vaccination strategy
against infections by African trypanosomes.
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